Monopar Therapeutics (MNPR) Change in Accured Expenses: 2017-2020
Historic Change in Accured Expenses for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to -$21,418.
- Monopar Therapeutics' Change in Accured Expenses rose 83.45% to -$21,418 in Q3 2020 from the same period last year, while for Sep 2020 it was $114,857, marking a year-over-year increase of 325.98%. This contributed to the annual value of $506,791 for FY2024, which is 138.00% up from last year.
- Monopar Therapeutics' Change in Accured Expenses amounted to -$21,418 in Q3 2020, which was down 113.13% from $163,152 recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Change in Accured Expenses ranged from a high of $304,229 in Q4 2019 and a low of -$331,106 during Q1 2020.
- Its 3-year average for Change in Accured Expenses is $12,895, with a median of -$11,248 in 2018.
- Within the past 5 years, the most significant YoY rise in Monopar Therapeutics' Change in Accured Expenses was 889.15% (2019), while the steepest drop was 1,050.57% (2019).
- Quarterly analysis of 4 years shows Monopar Therapeutics' Change in Accured Expenses stood at -$26,070 in 2017, then surged by 436.24% to $87,658 in 2018, then surged by 247.06% to $304,229 in 2019, then skyrocketed by 83.45% to -$21,418 in 2020.
- Its last three reported values are -$21,418 in Q3 2020, $163,152 for Q2 2020, and -$331,106 during Q1 2020.